This Article  • References  • Full text PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

I. Relapse Rates After One Year

Arthur Rifkin, MD; Fredric Quitkin, MD; Charles J. Rabiner, MD; Donald F. Klein, MD

Arch Gen Psychiatry. 1977;34(1):43-47.

Abstract
• In a sample of remitted, nonpsychotic schizophrenics, the relapse rate within one year was significantly higher for those patients taking placebo as opposed to those taking fluphenazine hydrochloride orally or fluphenazine decanoate. There were no differences in relapse rates between the two active drugs, but there were significantly more terminations due to toxicity from fluphenazine decanoate than from fluphenazine given orally, entirely due to the fact that in 35% of patients receiving fluphenazine decanoate, severe akinesia developed.

Author Affiliations
From the Department of Psychiatry, Long Island Jewish-Hillside Medical Center, Glen Oaks, New York. Drs Rifkin and Klein are presently with the New York State Psychiatric Institute and The College of Physicians and Surgeons, Columbia University, New York. Drs Rifkin, Quitkin, and Klein are now with the New York State Psychiatric Institute, New York.

Footnotes
Accepted for publication Feb 16, 1976.

Reprint requests to New York State Psychiatric Institute, 722 W 168th St, New York, NY 10032 (Dr Rifkin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Historical perspective on antipsychotic long-acting injections
Johnson
Br. J. Psychiatry 2009;195:S7-S12.
ABSTRACT | FULL TEXT  

Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert et al.
Arch Gen Psychiatry 1995;52:173-188.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Selection of Neuroleptic Dosage
Teicher and Baldessarini
Arch Gen Psychiatry 1985;42:636-637.
ABSTRACT  

Costs and Benefits of Two Doses of Fluphenazine
Marder et al.
Arch Gen Psychiatry 1984;41:1025-1029.
ABSTRACT  

Low-Dose Neuroleptic Treatment of Outpatient Schizophrenics: I. Preliminary Results for Relapse Rates
Kane et al.
Arch Gen Psychiatry 1983;40:893-896.
ABSTRACT  

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Mandel et al.
Arch Gen Psychiatry 1982;39:197-203.
ABSTRACT  

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane et al.
Arch Gen Psychiatry 1982;39:70-73.
ABSTRACT  

Prevention of Relapse in Schizophrenia: An Evaluation of Fluphenazine Decanoate
Schooler et al.
Arch Gen Psychiatry 1980;37:16-24.
ABSTRACT  

Fluphenazine and Social Therapy in the Aftercare of Schizophrenic Patients: Relapse Analyses of a Two-Year Controlled Study of Fluphenazine Decanoate and Fluphenazine Hydrochloride
Hogarty et al.
Arch Gen Psychiatry 1979;36:1283-1294.
ABSTRACT  

Long-Acting Oral vs Injectable Antipsychotic Drugs in Schizophrenics: A One-Year Double-Blind Comparison in Multiple Episode Schizophrenics
Quitkin et al.
Arch Gen Psychiatry 1978;35:889-892.
ABSTRACT  

Standard and Long-Acting Depot Neuroleptics in Chronic Schizophrenics: An 18-Month Open Multicentric Study
Simon et al.
Arch Gen Psychiatry 1978;35:893-897.
ABSTRACT  

Are Prophylactic Antiparkinson Drugs Necessary? A Controlled Study of Procyclidine Withdrawal
Rifkin et al.
Arch Gen Psychiatry 1978;35:483-489.
ABSTRACT  

Fluphenazine Decanoate, Oral Fluphenazine, and Placebo in Treatment of Remitted Schizophrenics: II. Rating Scale Data
Rifkin et al.
Arch Gen Psychiatry 1977;34:1215-1219.
ABSTRACT